We serve Chemical Name:1-fluoro-4-(2-isocyanoethyl)benzene CAS:244221-04-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1-fluoro-4-(2-isocyanoethyl)benzene
CAS.NO:244221-04-3
Synonyms:Benzene,1-fluoro-4-(2-isocyanoethyl);4-Fluorophenethylisocyanide
Molecular Formula:C9H8FN
Molecular Weight:149.16500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:149.06400
LogP:1.51820
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzene,1-fluoro-4-(2-isocyanoethyl) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluorophenethylisocyanide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzene,1-fluoro-4-(2-isocyanoethyl) Use and application,4-Fluorophenethylisocyanide technical grade,usp/ep/jp grade.
Related News: During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology. 1-fluoro-4-(2-isocyanoethyl)benzene manufacturer The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 1-fluoro-4-(2-isocyanoethyl)benzene supplier ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy. 1-fluoro-4-(2-isocyanoethyl)benzene vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 1-fluoro-4-(2-isocyanoethyl)benzene factory ICIG will also supply materials needed for the manufacture of other treatments in earlier stages of development, including neo-GAA, currently in preclinical development as a potential next-generation Pompe disease therapy.
